openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings and cautions
5 WARNINGS AND PRECAUTIONS See Boxed WARNINGS Life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients : Monitor closely, particularly during initiation of therapy. ( 5.4 ) Activities requiring mental alertness : Avoid engaging in hazardous tasks requiring mental alertness such as driving or operating machinery. ( 5.6 ) Risks of use in patients with head injury, impaired consciousness, increased intracranial pressure, or brain tumors : Avoid use. May increase intracranial pressure and obscure the clinical course of head injuries. ( 5.10 ) Seizures in patients with seizure disorders : Monitor during therapy. ( 5.11 ) Severe hypotension : Monitor during initiation of therapy. Avoid use in patients with circulatory shock. ( 5.12 ) Adrenal insufficiency : If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. ( 5.14 ) 5.1 Addiction, Abuse, and Misuse Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension contains hydrocodone, a Schedule II controlled substance. As an opioid, Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension exposes users to the risks of addiction, abuse, and misuse [ see Drug Abuse and Dependence (9) ] , which can lead to overdose and death [ see Overdosage (10) ] . Reserve Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient’s risk prior to prescribing Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, prescribe Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension for the shortest duration that is consistent with individual patient treatment goals , monitor all patients regularly for the development of addiction or abuse, and refill only after reevaluation of the need for continued treatment. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Addiction can occur at recommended dosages and if the drug is misused or abused. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Addiction can occur at recommended dosages and if the drug is misused or abused. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [ ]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product. Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [ see Patient Counseling Information (17) ]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product. 5.2 Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, including hydrocodone, one of the active ingredients in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Hydrocodone produces dose-related respiratory depression by directly acting on the brain stem respiratory center that controls respiratory rhythm and may produce irregular and periodic breathing. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression includes discontinuation of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, close observation, supportive measures, and use of opioid antagonists (e.g. naloxone), depending on the patient’s clinical status [ see Overdosage (10) ]. Carbon dioxide (CO 2 ) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, the risk is greatest during the initiation of therapy, when Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is used concomitantly with other drugs that may cause respiratory depression [ ], in patients with chronic pulmonary disease or decreased respiratory reserve, and in patients with altered pharmacokinetics or altered clearance (e.g. elderly, cachectic, or debilitated patients) [ ]. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, the risk is greatest during the initiation of therapy, when Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is used concomitantly with other drugs that may cause respiratory depression [ see Warnings and Precautions (5.8) ], in patients with chronic pulmonary disease or decreased respiratory reserve, and in patients with altered pharmacokinetics or altered clearance (e.g. elderly, cachectic, or debilitated patients) [ see Warnings and Precautions (5.4) ]. To reduce the risk of respiratory depression, proper dosing of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is essential [ ]. Monitor patients closely, especially within the first 24-72 hours of initiating therapy or when used in patients at higher risk. To reduce the risk of respiratory depression, proper dosing of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is essential [ see Dosage and Administration (2.1) , Warnings and Precautions (5.5) ]. Monitor patients closely, especially within the first 24-72 hours of initiating therapy or when used in patients at higher risk. Overdose of hydrocodone in adults has been associated with fatal respiratory depression, and the use of hydrocodone in children younger than 6 years of age has been associated with fatal respiratory depression when used as recommended. Accidental ingestion of even one dose of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, especially by children, can result in respiratory depression and death.Overdose of hydrocodone in adults has been associated with fatal respiratory depression, and the use of hydrocodone in children younger than 6 years of age has been associated with fatal respiratory depression when used as recommended. Accidental ingestion of even one dose of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, especially by children, can result in respiratory depression and death. 5.3 Risks of Use in Pediatric Populations Children are particularly sensitive to the respiratory depressant effects of hydrocodone [ see Warnings and Precautions (5.2) ]. Because of the risk of life-threatening respiratory depression and death, Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is contraindicated in children less than 6 years of age [ see Contraindications (4) ]. Use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in children also exposes them to the risks of addiction, abuse, and misuse [ ] which can lead to overdose and death [ ] Because the benefits of symptomatic treatment of cough associated with allergies or the common cold do not outweigh the risks of use of hydrocodone in pediatric patients, Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is not indicated for use in patients younger than 18 years of age [ ]. Use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in children also exposes them to the risks of addiction, abuse, and misuse [ see Drug Abuse and Dependence (9) ] , which can lead to overdose and death [ see Warnings and Precautions (5.1) , Overdosage (10) ] . Because the benefits of symptomatic treatment of cough associated with allergies or the common cold do not outweigh the risks of use of hydrocodone in pediatric patients, Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is not indicated for use in patients younger than 18 years of age [ see Indications (1) , Use in Specific Populations (8.4) ]. 5.4 Risks of Use in Other At-Risk Populations Unresponsive Cough The dosage of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension should not be increased if cough fails to respond; an unresponsive cough should be reevaluated in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [ ]. The dosage of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension should not be increased if cough fails to respond; an unresponsive cough should be reevaluated in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [ see Dosage and Administration (2.3) ]. Asthma and Other Pulmonary Disease The use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated [ ]. The use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated [ see Contraindications (4) ]. Opioid analgesics and antitussives, including hydrocodone, one of the active ingredients in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, should not be used in patients with acute febrile illness associated with productive cough or in patients with chronic respiratory disease where interference with ability to clear the tracheobronchial tree of secretions would have a deleterious effect on the patient’s respiratory function.Opioid analgesics and antitussives, including hydrocodone, one of the active ingredients in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, should not be used in patients with acute febrile illness associated with productive cough or in patients with chronic respiratory disease where interference with ability to clear the tracheobronchial tree of secretions would have a deleterious effect on the patient’s respiratory function. Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension [ ] Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension [ see Warnings and Precautions (5.2) ] . : Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [ ]. Elderly, Cachectic, or Debilitated Patients : Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [ see Warnings and Precautions (5.2) ]. Because of the risk of respiratory depression, avoid the use of opioid antitussives, including Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients with compromised respiratory function, patients at risk of respiratory failure, and in elderly, cachectic, or debilitated patients. If Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is prescribed, monitor such patients closely, particularly when initiating Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension and when Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is given concomitantly with other drugs that depress respiration [ ]. Because of the risk of respiratory depression, avoid the use of opioid antitussives, including Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients with compromised respiratory function, patients at risk of respiratory failure, and in elderly, cachectic, or debilitated patients. If Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is prescribed, monitor such patients closely, particularly when initiating Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension and when Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is given concomitantly with other drugs that depress respiration [ see Warnings and Precautions (5.8) ]. 5.5 Risk of Accidental Overdose and Death due to Medication Errors Dosing errors can result in accidental overdose and death. To reduce the risk of overdose and respiratory depression, ensure that the dose of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is communicated clearly and dispensed accurately [ see Dosage and Administration (2.1) ]. Advise patients to always use an accurate milliliter measuring device when measuring and administering Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Inform patients that household teaspoon is not an accurate measuring device and such use could lead to overdosage and serious adverse reactions [ ]. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate calibrated measuring device and can provide instructions for measuring the correct dose. Advise patients to always use an accurate milliliter measuring device when measuring and administering Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Inform patients that household teaspoon is not an accurate measuring device and such use could lead to overdosage and serious adverse reactions [ see Overdosage (10) ]. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate calibrated measuring device and can provide instructions for measuring the correct dose. 5.6 Activities Requiring Mental Alertness: Risks of Driving and Operating Machinery Hydrocodone and chlorpheniramine, two of the active ingredients in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Avoid concurrent use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur [ see Warnings and Precautions (5.8) . 5.7 Risks from Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone and prolong opioid adverse reactions, which may cause potentially fatal respiratory depression [ see Warnings and Precautions (5.2) ], particularly when an inhibitor is added after a stable dose of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is achieved. Similarly, discontinuation of a CYP3A4 inducer, such as rifampin, carbamazepine, and phenytoin, in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension-treated patients may increase hydrocodone plasma concentrations and prolong opioid adverse reactions. Concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension with CYP3A4 inducers or discontinuation of an CYP3A4 inhibitor could decrease hydrocodone plasma concentrations, decrease opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to hydrocodone.Concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension with CYP3A4 inducers or discontinuation of an CYP3A4 inhibitor could decrease hydrocodone plasma concentrations, decrease opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to hydrocodone. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients who are taking a CYP3A4 inhibitor or inducer. If concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension with a CYP3A4 inhibitor or inducer is necessary, monitor patients for signs and symptoms that may reflect opioid toxicity and opioid withdrawal [ ]. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients who are taking a CYP3A4 inhibitor or inducer. If concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension with a CYP3A4 inhibitor or inducer is necessary, monitor patients for signs and symptoms that may reflect opioid toxicity and opioid withdrawal [ see Drug Interactions ( 7.2 , 7.3 ) ]. 5.8 Risks from Concomitant Use with Benzodiazepines or other CNS Depressants Concomitant use of opioids, including Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, with benzodiazepines, or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Because of these risks, avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol [ see Drug Interactions ( 7.1 , 7.5 ) ]. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol.Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol. Advise both patients and caregivers about the risks of respiratory depression and sedation if Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is used with benzodiazepines, alcohol, or other CNS depressants [ ] Advise both patients and caregivers about the risks of respiratory depression and sedation if Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is used with benzodiazepines, alcohol, or other CNS depressants [ see Patient Counseling Information (17) ] . Patients must not consume alcoholic beverages, or prescription or non-prescription products containing alcohol, while on Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension therapy. The co-ingestion of alcohol with Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may result in increased plasma levels and a potentially fatal overdose of hydrocodone [ ]. Patients must not consume alcoholic beverages, or prescription or non-prescription products containing alcohol, while on Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension therapy. The co-ingestion of alcohol with Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may result in increased plasma levels and a potentially fatal overdose of hydrocodone [ see Drug Interactions (7.1) ]. 5.9 Risks of Use in Patients with Gastrointestinal Conditions Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus [ see Contraindications (4) ]. The use of hydrocodone in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of anticholinergics with Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may produce paralytic ileus [ ]. The concurrent use of anticholinergics with Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may produce paralytic ileus [ see Drug Interactions (7.10) ]. The hydrocodone in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may result in constipation or obstructive bowel disease, especially in patients with underlying intestinal motility disorders. Use with caution in patients with underlying intestinal motility disorders.The hydrocodone in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may result in constipation or obstructive bowel disease, especially in patients with underlying intestinal motility disorders. Use with caution in patients with underlying intestinal motility disorders. The hydrocodone in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may cause spasm of the sphincter of Oddi, resulting in an increase in biliary tract pressure. Opioids may cause increases in serum amylase [ ]. Monitor patients with biliary tract disease, including acute pancreatitis for worsening symptoms. The hydrocodone in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may cause spasm of the sphincter of Oddi, resulting in an increase in biliary tract pressure. Opioids may cause increases in serum amylase [ see Warnings and Precautions (5.15) ]. Monitor patients with biliary tract disease, including acute pancreatitis for worsening symptoms. 5.10 Risks of Use in Patients with Head Injury, Impaired Consciousness, Increased Intracranial Pressure, or Brain Tumors Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients with head injury, intracranial lesions, or a pre-existing increase in intracranial pressure. In patients who may be susceptible to the intracranial effects of CO 2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may reduce respiratory drive, and the resultant CO 2 retention can further increase intracranial pressure. Furthermore, opioids produce adverse reactions that may obscure the clinical course of patients with head injuries. 5.11 Increased Risk of Seizures in Patients with Seizure Disorders The hydrocodone and chlorpheniramine in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension therapy. 5.12 Severe Hypotension Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [ see Drug Interactions (7.5) ] . Monitor these patients for signs of hypotension after initiating Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. In patients with circulatory shock, Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients with circulatory shock.In patients with circulatory shock, Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in patients with circulatory shock. 5.13 Neonatal Opioid Withdrawal Syndrome Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is not recommended for use in pregnant women. Prolonged use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. [ see Use in Specific Populations (8.1) , Patient Counseling Information (17) ] 5.14 Adrenal Insufficiency Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency. 5.15 Drug/Laboratory Test Interactions Because opioid agonists may increase biliary tract pressure, with resultant increase in plasma amylase or lipase levels, determination of these enzyme levels may be unreliable for 24 hours after administration of a dose of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension.